Because genes exert their effects on complex phenotypes, such as mental illness, through intermediary molecular and physiological mechanisms, these "intermediate phenotypes" should have a simpler genetic architecture. This should make it easier to detect the effects of specific genetic variants. Intermediate phenotypes referable to hippocampus have received attention because of its role in neuropsychiatrie disorders such as schizophrenia. Promising intermediate phenotypes have included measures of episodic memory, hippocampal activation assayed with functional magnetic resonace imaging (fMRI), and hippocampal volume assayed with MRI, among others. In addition to these relatively complex intermediate phenotypes, each gene also has related phenotypic measures based on its function. For example, the dopamine D~2~ receptor exerts its effects by modulating intracellular cyclic adenosine monophosphate (cAMP) levels and therefore one can study the functional effects of mutations in the D~2~ gene by examining downstream effects on cAMP levels. Thus, the impact of a specific genetic variant in a gene can be studied at basic cellular level, as well as at the systems level.

*BDNF* is an obvious candidate gene for hippocampal function in humans because studies in animals have shown BDNF to be a critical mediator of episodic memory. For example, BDNF plays an essential role in the molecular mechanisms of both early and late phases of long-term potentiation (LTP) through both presynaptic and postsynaptic mechanisms. To exert these effects, BDNF is packaged and transported to dendrites, where it is released and acts as a retrograde messenger. Despite this work in nonhumans, it has been unclear what role BDNF played in the greatly expanded, verbally mediated episodic memory in humans.

The *BDNF* gene is 66.8 kilobases, has 9 exons, and produces at least 6 splice variants. All 5′ exons are spliced out and only the final 3′ exon is translated into protein. Translation produces a precursor protein, which is packaged into secretory vesicles and eventually cleaved at amino acid 128 to form the mature BDNF protein. The *BDNF* gene was recently found to contain at least one common polymorphism that changes amino acid sequence. This is the val66met polymorphism at codon 66, which creates a valine to methionine substitution in the preprotein. Other missense single nucleotide polymorphisms (SNPs) have been described, but appear to be uncommon. Because val66met is only in the preprotein, it has no effect on the structure or in vitro activity of the mature BDNF protein.

The relevance of this polymorphism for humans was first examined in a study of intermediate phenotypes related to schizophrenia. In a group of 641 subjects, those with a *val* allele were found to have significantly better scores on a test of episodic memory, compared with subjects homozygous for the *met* allele.^[@ref1]^ This study then showed that the *met* allele altered the intracellular trafficking and release of BDNF. In cultured rodent hippocampal neurons, the *val* form of the preprotein was packaged into secretory vesicles and released from dendrites. In contrast, the *met* allele was not well packaged into vesicles, but instead formed clumps around the nucleus. Stimulated release in *met*-containing neurons was markedly reduced. These experiments suggested that the *met* allele exerts its deleterious effects on episodic memory, because it is not released properly in the hippocampus during formation of episodic memories.

The effects of the val66met polymorphism on episodic memory scores were weak and by themselves initially not convincing. However, results from additional imaging studies offered a remarkable degree of convergent evidence. First, magnetic resonance spectroscopy was used to assay *N*-acetylaspartate (NAA), an intraneuronal metabolite closely correlated with tissue glutamate levels. Reduced NAA levels have been reported in many neuropsychiatrie disorders, including schizophrenia. NAA is an indirect measure of synaptic abundance and/or glutamate neurotransmission. In a cohort of 300 subjects, those with a *met* allele had reduced NAA compared with *val/val* subjects, consistent with the memory findings.^[@ref1]^ This suggests that deficient impulse-dependent BDNF secretion might produce a long-lasting reduction in dendritic or neuronal density. Second, fMRI was used to assay hippocampal BOLD (blood oxygenation level-dependent) signals during an episodic memory task. Fourteen *val/val* subjects were compared with 14 subjects with a *met* allele *(val/met* and *met/met* groups were combined because the latter are rare).^[@ref2]^ Consistent with the cognitive and NAA findings, the *met* allele group showed reduced hippocampal activation during encoding and retrieval *([Figure 1](#DialoguesClinNeurosci-7-136-g001){ref-type="fig"})*. Greater hippocampal activation had previously been shown to correlate with better memory. Thus, the *val* allele\'s ability to be secreted by dendrites appeared to produce downstream effects on hippocampal blood flow during encoding of memories and this was detectable in sample of only 28 subjects.

![Effect of brain-derived neurotrophic factor (BDNF) val66met on hippocampal activation during an encoding task. Statistical maps showing where *val/val* subjects have greater activation compared with subjects with 1 or 2 *met* alleles during an incidental encoding task. The highlighted areas are statistical results overlaid onto averaged structural magnetic resonance images. **A.** Regions in right hippocampus and para hippocampal gyrus where *val/val* subjects show greater activation compared with *met* subjects during the initial presentation of a picture, when subjects encode a memory trace. **B.** Regions in left and right parahippocampal gyrus where *val/val* subjects show greater activation compared with subjects with a *met* allele during the second presentation of a picture, when subjects have to retrieve a memory trace.\
Reproduced from reference 2: Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor va I66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. *J Neurosci.* 2003;23:6690-6694. Copyright © 2003. Society for Neuroscience.](DialoguesClinNeurosci-7-136-g001){#DialoguesClinNeurosci-7-136-g001}

Similar effects were seen in two other imaging studies. A second fMRI study used a working memory task where hippocampal deactivation is typically correlated with superior performance. In two separate cohorts of 13 and 17 subjects, respectively, subjects with a *met* allele demonstrated the deleterious pattern of failure to deactivate hippocampus.^[@ref1]^ Next, a semiautomated morphometric technique was used to evaluate BDNF\'s effects on actual hippocampal volume.^[@ref3]^ Pezawas et al^[@ref3]^ found that 42 *met* carriers had a 12 % to 15 % reduction in hippocampal volume compared with 69 *val/val* subjects *([Figure 2](#DialoguesClinNeurosci-7-136-g002){ref-type="fig"})*. Reduced volume is consistent with reduced NAA, again suggesting that the *met* allele\'s reduced impulse-dependent release impacted dendritic or neuronal density. In all, these four neuroimaging studies are remarkable for both their consistency in showing deleterious effects of the *met* allele and because these effects were detected using such modest sample sizes.

![Effect of brain-derived neurotrophic factor (BDNF) val66met on hippocampal volume. Statistical maps of *t*-transformed hippocampal volume differences between *val/val* subjects and those with a *met* allele. Subjects with a *met* allele have reduced volumes bilaterally in the highlighted areas compared with *val/val* subjects.\
Reproduced from reference 3: Pezawas L, Verchinshi BA, Mattay VS, et al. The brain-derived neurotrophic factor val66met polymorphism and variants in human cortical morphology. *J Neurosci.* 2004;24:10099-10102. Copyright © 2004. Society for Neuroscience.](DialoguesClinNeurosci-7-136-g002){#DialoguesClinNeurosci-7-136-g002}

While neuroimaging studies offer convergent evidence that the BNDF val66met polymorphism affects hippocampal function, it remains unclear what role this SNP plays in psychiatric disorders. BDNF has been weakly associated with several psychiatric disorders, including schizophrenia, mood, and anxiety disorders. Surprisingly, the *val* allele is often associated with illness.^[@ref4]^ Whether the causative variant is val66met or a nearby variant in linkage disequilibrium, other steps in the causal chain remain to be elucidated. Nevertheless, the discovery that val66met itself alters intracellular processing and release of BDNF, and is associated with hippocampal physiological responses, in vivo NAA levels, hippocampal size, and hippocampal-mediated cognition, increases the a priori likelihood that it plays a role in disorders related to hippocampal function.

More broadly, these data demonstrate that intermediate phenotypes, particularly neuroimaging phenotypes, can play a substantial role in elucidating the mechanisms by which specific genetic variants impact human brain function and risk for common neuropsychiatric disorders.
